Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Finished Goods (2016 - 2025)

Historic Finished Goods for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $20.2 million.

  • Collegium Pharmaceutical's Finished Goods rose 2312.65% to $20.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.2 million, marking a year-over-year increase of 2312.65%. This contributed to the annual value of $17.8 million for FY2024, which is 1712.26% up from last year.
  • As of Q3 2025, Collegium Pharmaceutical's Finished Goods stood at $20.2 million, which was up 2312.65% from $20.2 million recorded in Q2 2025.
  • Collegium Pharmaceutical's 5-year Finished Goods high stood at $36.9 million for Q1 2022, and its period low was $9.5 million during Q2 2021.
  • Its 5-year average for Finished Goods is $16.5 million, with a median of $15.2 million in 2023.
  • Its Finished Goods has fluctuated over the past 5 years, first surged by 28078.47% in 2022, then tumbled by 6280.54% in 2023.
  • Collegium Pharmaceutical's Finished Goods (Quarter) stood at $12.7 million in 2021, then rose by 27.77% to $16.2 million in 2022, then fell by 6.29% to $15.2 million in 2023, then rose by 17.12% to $17.8 million in 2024, then increased by 13.64% to $20.2 million in 2025.
  • Its last three reported values are $20.2 million in Q3 2025, $20.2 million for Q2 2025, and $18.5 million during Q1 2025.